CY1113488T1 - Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας - Google Patents

Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας

Info

Publication number
CY1113488T1
CY1113488T1 CY20121101221T CY121101221T CY1113488T1 CY 1113488 T1 CY1113488 T1 CY 1113488T1 CY 20121101221 T CY20121101221 T CY 20121101221T CY 121101221 T CY121101221 T CY 121101221T CY 1113488 T1 CY1113488 T1 CY 1113488T1
Authority
CY
Cyprus
Prior art keywords
medicine
therapy treatment
agent
operative therapy
reducing
Prior art date
Application number
CY20121101221T
Other languages
English (en)
Inventor
Giovanni Paganelli
Paolo Carminati
Umberto Veronesi
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of CY1113488T1 publication Critical patent/CY1113488T1/el

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Η παρούσα εφεύρεση περιγράφει τη χρήση ενός παράγοντα εξοπλισμένου με τροπισμό όγκου, σε συνδυασμό με έναν άλλο παράγοντα με αντικαρκινική δραστικότητα και με μία χημική συγγένεια προς τον πρώτο παράγοντα για την παρασκευή ενός φαρμάκου, χρήσιμου για την δύο βαθμίδων περιεγχειρητική θεραπεία συμπαγών όγκων. Τα πλεονεκτήματα της παρούσας εφεύρεσης συνίστανται εις τον μεγαλύτερο αποτελεσματικό εντοπισμό της αντικαρκινικής της δραστικότητας, εις τη μείωση του αριθμού των βαθμίδων χορήγησης και εις τη δυνατότητα μείωσης των αντικαρκινικών δόσεων με μία προκύπτουσα μείωση εις τις παρενέργειες, αλλά χωρίς καμία απώλεια αποτελεσματικότητας.
CY20121101221T 2003-04-24 2012-12-14 Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας CY1113488T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000196A ITRM20030196A1 (it) 2003-04-24 2003-04-24 Uso di reagenti per la preparazione di un medicamento
EP04726249A EP1615668B1 (en) 2003-04-24 2004-04-07 A medicament for the two-step perioperative therapy of solid tumours by radioimmunotherapy

Publications (1)

Publication Number Publication Date
CY1113488T1 true CY1113488T1 (el) 2016-06-22

Family

ID=29765781

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101221T CY1113488T1 (el) 2003-04-24 2012-12-14 Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας

Country Status (20)

Country Link
US (1) US7935346B2 (el)
EP (1) EP1615668B1 (el)
JP (1) JP4949016B2 (el)
KR (1) KR20060005383A (el)
CN (1) CN1777446A (el)
AR (1) AR044052A1 (el)
AU (1) AU2004231377B2 (el)
BR (1) BRPI0409604A (el)
CA (1) CA2522580C (el)
CY (1) CY1113488T1 (el)
DK (1) DK1615668T3 (el)
ES (1) ES2398389T3 (el)
HR (1) HRP20121052T8 (el)
IT (1) ITRM20030196A1 (el)
MX (1) MXPA05011293A (el)
PL (1) PL1615668T3 (el)
PT (1) PT1615668E (el)
SI (1) SI1615668T1 (el)
TW (1) TWI368518B (el)
WO (1) WO2004093916A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030196A1 (it) 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento
CN101772353B (zh) 2007-08-02 2013-03-06 希格马托制药工业公司 在受治疗组织中展现高停留时间的氧化的抗生物素蛋白
IT1398977B1 (it) 2009-06-25 2013-03-28 Icgeb Agente anticancro specifico per i tumori cerebrali con meccanismo di soppressione di recq1
PL2739314T3 (pl) * 2011-08-02 2019-09-30 Alfasigma S.P.A. Kompozycja farmaceutyczna utlenionej awidyny odpowiednia do inhalacji
US20160331853A1 (en) * 2014-01-21 2016-11-17 The Trustees Of Columbia University In The City Of New York Compositions for radiotherapy and uses thereof
EP3316871A4 (en) 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York TALKED COMPOSITION AND USES THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
IT1245748B (it) 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
EP0733066B1 (en) 1993-12-07 2003-11-19 NeoRx Corporation Pretargeting methods and compounds
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
EP1395226A4 (en) 2001-06-11 2005-03-30 Univ Miami USE OF RADIOPHARMETHIC COMPLEXES TO IMPROVE TRANSPLANT TOLERANCE
ITRM20020071A1 (it) 2002-02-11 2003-08-11 Sigma Tau Ind Farmaceuti Contenitore per flacone di radiofarmaco, e corredo per la sua infusione in un paziente o per il suo trasferimento altrove.
US20030228256A1 (en) 2002-06-11 2003-12-11 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
ITRM20030196A1 (it) 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento

Also Published As

Publication number Publication date
AR044052A1 (es) 2005-08-24
PL1615668T3 (pl) 2013-03-29
HRP20121052T8 (en) 2013-03-31
AU2004231377B2 (en) 2010-08-05
AU2004231377A1 (en) 2004-11-04
CN1777446A (zh) 2006-05-24
ES2398389T3 (es) 2013-03-15
EP1615668A1 (en) 2006-01-18
ITRM20030196A0 (it) 2003-04-24
BRPI0409604A (pt) 2006-04-18
KR20060005383A (ko) 2006-01-17
PT1615668E (pt) 2013-01-14
SI1615668T1 (sl) 2013-01-31
JP4949016B2 (ja) 2012-06-06
DK1615668T3 (da) 2013-02-04
US20060251579A1 (en) 2006-11-09
TWI368518B (en) 2012-07-21
WO2004093916A8 (en) 2005-11-03
CA2522580A1 (en) 2004-11-04
WO2004093916A1 (en) 2004-11-04
US7935346B2 (en) 2011-05-03
CA2522580C (en) 2013-08-06
HRP20121052T1 (hr) 2013-01-31
MXPA05011293A (es) 2006-01-24
EP1615668B1 (en) 2012-12-05
ITRM20030196A1 (it) 2004-10-25
JP2006524235A (ja) 2006-10-26
TW200501984A (en) 2005-01-16

Similar Documents

Publication Publication Date Title
CY1113488T1 (el) Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
CY1120445T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
CY1111478T1 (el) Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης
NO20072529L (no) Cytotoksisk utforming for kombinasjonsbehandling
AR033175A1 (es) Usos farmaceuticos de bisfosfonatos
CY1112361T1 (el) Σκευασματα για αντικαρκινικη θεραπεια που περιεχουν εκτεϊνασκιδινη 743
UY27186A1 (es) Formulación farmacéutica
ATE534378T1 (de) Titrierung von tapentadol
CY1108384T1 (el) Διαδερμικη δοσολογια βουπρενορφινης για αναλγησια
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AR032293A1 (es) Estuche farmaceutico
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
HK1068606A1 (en) Novel aminobenzoephenones
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
NO20044498L (no) Kombinasjonsterapi for behandling av cancer
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
WO2006043031A3 (en) Class iii slrp for the treatment of cancer
SE0300535D0 (sv) Treatment of burns
MX2023005072A (es) Bloqueo de cd47 y terapias combinadas de los mismos para reducir la inflamacion vascular.
BR0311141A (pt) Interação sinergìstica de abacavir e alovudine
DK1835922T3 (da) Kombinationsbehandling mod multipel sklerose